Skip to main content
Local News

CDRD Appoints Matthew J. Carlyle Chief Financial Officer

By May 12, 2017No Comments

The Centre for Drug Research and Development (CDRD), Canada’s national drug development and commercialization engine is pleased to announce the appointment of Matthew J. Carlyle, CFA, as Chief Financial Officer effective immediately.

Mr. Carlyle brings extensive experience and relationships across global biotechnology and venture capital to CDRD, having been a partner of a national venture capital firm, CFO of a publicly traded biotech, and CFO of a number of private life sciences companies.

Most recently, Mr. Carlyle was the Chief Financial Officer of Viable Healthworks Corp., and from 2004 to 2013, was Chief Financial Officer of Allon Therapeutics Inc. Previously, he served in Corporate Finance and Development roles for a number of public and private life science and technology companies, and has been involved in raising approximately $200M. Mr. Carlyle is a founding Partner of NDI Capital, a private investment management company focused on investing in high potential life science and healthcare companies. He holds the Chartered Financial Analyst designation and is a member of the Association for Investment Management and Research, and the Vancouver Society of Financial Analysts.

CDRD Chair, Mr. Don Avison commented, “On behalf of the CDRD Board of Directors, I am pleased to welcome Mr. Carlyle. We are excited to bring someone of Matthew’s broad financial background to the organization, and know he is going to be a tremendous asset in helping drive CDRD to its next level of success as a global bridge translating discoveries into innovative therapeutic products and improved health outcomes.”

Mr. Gordon McCauley, President and CEO of CDRD added, “I have had the pleasure of working alongside Matthew for a number of years, and know he will make a tremendous addition to the CDRD leadership team as we set the course for the future of CDRD, and continue to work with our partners across the country to identify and advance promising discoveries and transform them into validated investments.”

– See more at: